Not Signed In -
Schizophrenia |
Schizoid personality disorder; Schizotypal personality disorder |
Clinical Trial: Evaluate the Efficacy in the Prevention of Recurrence of the Symptoms of Schizophrenia
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo (sometimes called a sugar pill) in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in subjects with stable and symptomatic schizophrenia.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Schizophrenia | Drug: R092670 | Phase III |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Prevention
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Meet the diagnostic criteria for schizophrenia according to DSM-IV-TM for at least 1 year before screening;
- PANSS score of <120;
- BMI > or equal to 15.0;
- Effective birth control or postmenopausal for at least 2 years;
- reside at the same address for at least 30 days
Exclusion Criteria:
- subjects unable to provide their own consent;
- involuntarily committed to psychiatric hospitalization;
- history of any severe preexisting gastrointestinal narrowing or inability to swallow the medication whole with water;
- female subjects who are pregnant, breastfeeding, or planning to become pregnant;
- MAOI antidepressants;
- hypersensitivity to egg yolks, soybean oil, phospholipids, and glycerol
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00111189
California
Clinical Innovations, Santa Ana, California, 92705, United States; Recruiting
Debra Hoffmeyer 714-547-4100
Himasiri DeSilva, Principal Investigator
Himasiri DeSilva, Principal Investigator
Comprehensive NeuroScience Inc, Cerritos, California, 90703, United States; Recruiting
Steve Ingalls 562-924-4262
David Sack, Principal Investigator
David Sack, Principal Investigator
Florida
Berma Research Group, Hialeah, Florida, 33016, United States; Recruiting
Dalia Alvarez 305-702-9453
Alfredo Pujol, Principal Investigator
Alfredo Pujol, Principal Investigator
Illinois
Mid America Psychiatric Consultants, Granite City, Illinois, 62040, United States; Recruiting
Susan Akins 618-876-7256
Asif Habib, Principal Investigator
Asif Habib, Principal Investigator
Uptown Research Institute LLC, Chicago, Illinois, 60640, United States; Recruiting
Blake Vaugh 773-989-9871
John Sonnenberg, Principal Investigator
John Sonnenberg, Principal Investigator
Louisiana
Brentwood Research Institute, Shreveport, Louisiana, 71101, United States; Recruiting
Vickie Strong 318-227-4565
Guy Brannon, Principal Investigator
Guy Brannon, Principal Investigator
Missouri
MedClin Research Inc, St. Louis, Missouri, 63118, United States; Recruiting
Mary Poupard 314-614-1500
Surrendra Chaganti, Principal Investigator
Surrendra Chaganti, Principal Investigator
New Jersey
CNS Research Institute, Clementon, New Jersey, 08021, United States; Recruiting
Sandy Romano 856-566-9000
Steven Glass, Principal Investigator
Steven Glass, Principal Investigator
New York
Neurobehavioral Research Inc, Lawrence, New York, 11559, United States; Recruiting
Maureen Legaulat 516-295-7230
Ronald Brenner, Principal Investigator
Ronald Brenner, Principal Investigator
Oklahoma
IPS Research, Oklahoma City, Oklahoma, 73103, United States; Recruiting
Monica Bottoms 405-235-8188
Louise Beckett, Principal Investigator
Louise Beckett, Principal Investigator
Texas
Tri County MHMR Services, Conroe, Texas, 77304, United States; Recruiting
Darlene Smith 936-525-2647
Irving Belz, Principal Investigator
Irving Belz, Principal Investigator
Community Clinical Research, Austin, Texas, 78756, United States; Recruiting
Sarah Fowler 512-323-2622
David Brown, Principal Investigator
David Brown, Principal Investigator
University Hills Clinical Research, Irving, Texas, 75062, United States; Recruiting
Brandy Castano 972-717-6262
Mary Ann Knesevich, Principal Investigator
Mary Ann Knesevich, Principal Investigator
InSite Clinical Research, Desoto, Texas, 75115, United States; Recruiting
Susan Allen 972-283-6286
Raj Shiwach, Principal Investigator
Raj Shiwach, Principal Investigator
More Information
Study ID Numbers: R092670-PSY-3001
Record last reviewed: May 2005
Last Updated: May 17, 2005
Record first received: May 17, 2005
ClinicalTrials.gov Identifier: NCT00111189
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-05-24
Record last reviewed: May 2005
Last Updated: May 17, 2005
Record first received: May 17, 2005
ClinicalTrials.gov Identifier: NCT00111189
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-05-24
Resources
- Ask NOAH About: Schizoaffective Disorder Fact Sheet (New York Online Access to Health, The New York Hospital Cornell Medical Center (NOAH))
- Ask NOAH About: Schizophrenia Fact Sheet (New York Online Access to Health, The New York Hospital Cornell Medical Center (NOAH))
email this page
print this page
bookmark this page
feedback on this page
